É. Hughes

Most-cited papers

1. Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1.

   J. McBryan, Sarah M. Theissen, Christopher Byrne, É. Hughes +6 more

   2012Cancer Research78 citations Open access

   Semantic Scholar

   Save

2. Sortilin inhibition limits secretion-induced progranulin-dependent breast cancer progression and cancer stem cell expansion

   S. Rhost, É. Hughes, H. Harrison, S. Rafnsdottir +8 more

   2018Breast Cancer Research66 citations Open access

   Semantic Scholar

   Save

3. HOXC11–SRC-1 regulation of S100beta in cutaneous melanoma: new targets for the kinase inhibitor dasatinib

   C. DeBlacam, Christopher Byrne, É. Hughes, M. McIlroy +3 more

   2011British Journal of Cancer26 citations Open access

   Semantic Scholar

   Save

4. S100β as a serum marker in endocrine resistant breast cancer

   S. Charmsaz, É. Hughes, F. Bane, P. Tibbitts +9 more

   2017BMC Medicine24 citations Open access

   Semantic Scholar

   Save

5. Hypoxia‐induced secretion stimulates breast cancer stem cell regulatory signalling pathways

   Hanna Jacobsson, H. Harrison, É. Hughes, E. Persson +8 more

   2019Molecular Oncology23 citations Open access

   Semantic Scholar

   Save

6. Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer

   K. Berger, S. Rhost, S. Rafnsdottir, É. Hughes +5 more

   2021BMC Cancer14 citations Open access

   Semantic Scholar

   Save

7. Abstract P6-04-01: Global analysis of breast cancer metastasis suggests cellular reprogramming is central to the endocrine resistant phenotype.

   J. Bolger, D. McCartan, C. Walsh, Yuan Hao +5 more

   20124 citations

   Semantic Scholar

   Save

8. Abstract P2-06-11: Sortilin targeted therapy in breast cancer with elevated progranulin expression

   K. Berger, S. Rhost, É. Hughes, H. Harrison +8 more

   2019Poster Session Abstracts1 citations

   Semantic Scholar

   Save

9. Protein bomarkers Ki67, HOXC10 and HOXC11 for the prediction of response to endocrine treatment in breast cancer

   YH Soon, F. Bane, É. Hughes, L. Young

   2015BMC Proceedings1 citations Open access

   Semantic Scholar

   Save

10. Tumor Co-Expression of Progranulin and Sortilin Identifies a Highly Malignant Subgroup of Breast Cancer

    K. Berger, S. Rhost, S. Rafnsdottir, É. Hughes +5 more

    20200 citations Open access

    Semantic Scholar

    Save

11. Commentary: Sortilin Inhibition Limits Secretion-induced Progranulin-dependent Breast Cancer Progression and Cancer Stem Cell Expansion

    S. Rhost, É. Hughes, A. Ståhlberg, G. Landberg

    2019Journal of Human and Clinical Genetics0 citations Open access

    Semantic Scholar

    Save

12. Abstract P3-04-03: S100β as a predictive biomarker and monitoring tool in endocrine resistant breast cancer

    S. Charmsaz, É. Hughes, Christopher Byrne, F. Bane +4 more

    20170 citations

    Semantic Scholar

    Save

13. Development of the biomarker S100β in metastatic endocrine resistant breast cancer

    É. Hughes

    20120 citations

    Semantic Scholar

    Save

14. P5-12-01: Aromatase Inhibitor Specific Metastasis Is Driven by the Steroid Receptor Coactivator SRC-1.

    Sm Theissen, J. McBryan, Christopher Byrne, É. Hughes +3 more

    20110 citations

    Semantic Scholar

    Save